These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 26943702

  • 1. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
    Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C, Sindhu H.
    Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
    [Abstract] [Full Text] [Related]

  • 2. Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.
    Kapor S, Momčilović S, Kapor S, Mojsilović S, Radojković M, Apostolović M, Filipović B, Gotić M, Čokić V, Santibanez JF.
    Adv Exp Med Biol; 2023 Apr; 1408():273-290. PubMed ID: 37093433
    [Abstract] [Full Text] [Related]

  • 3. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
    Keski H.
    Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
    [Abstract] [Full Text] [Related]

  • 4. Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms.
    Liang F, Liang X, Pan L, Jin Q, Deng J, Hong M, Wei W, Hao Z, Ren H, Wang H, Chen X.
    Clin Exp Med; 2024 May 21; 24(1):106. PubMed ID: 38771542
    [Abstract] [Full Text] [Related]

  • 5. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
    Čokić VP, Mossuz P, Han J, Socoro N, Beleslin-Čokić BB, Mitrović O, Subotički T, Diklić M, Leković D, Gotić M, Puri RK, Noguchi CT, Schechter AN.
    PLoS One; 2015 May 21; 10(8):e0135463. PubMed ID: 26275051
    [Abstract] [Full Text] [Related]

  • 6. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B, Diral E, Donsante S, Di Marzo N, Mottadelli F, Cardinale L, Dander E, Isimbaldi G, Pioltelli P, Biondi A, Riminucci M, D'Amico G, Elli EM, Pievani A, Serafini M.
    Ann Hematol; 2021 Jan 21; 100(1):105-116. PubMed ID: 33089365
    [Abstract] [Full Text] [Related]

  • 7. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wang JC, Chen C, Kundra A, Kodali S, Pandey A, Wong C, Cheung T, Gotlieb V, Joseph G, Tribie S.
    Leuk Res; 2019 Apr 21; 79():52-59. PubMed ID: 30851544
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.
    Thromb Res; 2014 Feb 21; 133(2):218-21. PubMed ID: 24309205
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
    Koopmans SM, Schouten HC, van Marion AM.
    Histol Histopathol; 2015 Feb 21; 30(2):151-61. PubMed ID: 25196073
    [Abstract] [Full Text] [Related]

  • 12. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.
    Asian Pac J Cancer Prev; 2015 Feb 21; 16(12):5013-8. PubMed ID: 26163633
    [Abstract] [Full Text] [Related]

  • 13. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C, Huh HJ, Mun YC, Seong CM, Chung WS, Huh J.
    Int J Lab Hematol; 2015 Apr 21; 37(2):181-9. PubMed ID: 24845343
    [Abstract] [Full Text] [Related]

  • 14. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M.
    Blood; 2008 Sep 15; 112(6):2199-204. PubMed ID: 18451307
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy.
    Javorniczky NR, Wehrle J, Ihorst G, Hupfer V, Aumann K, Pfeifer D, Niemöller C, Bleul S, Pantic M, Werner M, Duyster J, Finke J, Engelhardt M, von Bubnoff N, Waller CF, Pahl HL, Becker H.
    Leuk Res; 2020 Nov 15; 98():106454. PubMed ID: 32971364
    [Abstract] [Full Text] [Related]

  • 16. The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
    Kiem D, Wagner S, Magnes T, Egle A, Greil R, Melchardt T.
    Int J Mol Sci; 2021 Sep 03; 22(17):. PubMed ID: 34502471
    [Abstract] [Full Text] [Related]

  • 17. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
    O'Sullivan J, Mead AJ.
    Adv Biol Regul; 2019 Jan 03; 71():55-68. PubMed ID: 30528537
    [Abstract] [Full Text] [Related]

  • 18. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N.
    Ann Hematol; 2018 Jan 03; 97(1):109-121. PubMed ID: 29143068
    [Abstract] [Full Text] [Related]

  • 19. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.
    Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, Rampal RK, Dueck A, Najfeld V.
    Blood Adv; 2018 Dec 26; 2(24):3581-3589. PubMed ID: 30563882
    [Abstract] [Full Text] [Related]

  • 20. [Clinical Characteristics of Patients with JAK2 Gene Mutation Myeloproliferative Neoplasms].
    Li YJ, Zhu SR, Liu WY, Ming J, Wang ZQ, Zhang SS, Hu XM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct 26; 29(5):1533-1539. PubMed ID: 34627436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.